SEHK:2616Biotechs
CStone Pharmaceuticals (SEHK:2616) Valuation Check After New UK Approval For Sugemalimab In Stage III Lung Cancer
CStone Pharmaceuticals (SEHK:2616) is back on investors radar after the UK regulator granted a new indication for its cancer drug sugemalimab, extending its use in specific stage III lung cancer patients.
See our latest analysis for CStone Pharmaceuticals.
The MHRA decision lands at a time when CStone’s 1 month share price return of 30.91% and 90 day share price return of 18.75% suggest building momentum. However, the 1 year total shareholder return of 100.30% contrasts with a 5 year total...